#ODX 1/8
Yes, it’s more research 😜
The Gov have ordered Automated LFT Cassette Assembly Equipment from Huxley Bertram Engineering based in Cambridge. It’s worth noting that Omega also have a base in Cambridgeshire and Mologic in Bedford (45 mins away).
https://t.co/bR8T5zefS5
#AVCT
‘’Great accuracy leaving healthy cells unharmed’’
‘’Life-changing for many cancer patients’’
‘’AVA6000 - a tumour activated form of dox - is now in clinic, and we couldn’t be more excited!’’
Neither could we, Christiana.
🦄
Context on the DLT within C2 👇🏽
‘’This was felt not to be clearly anthracycline related cardiotoxicity’’
As mentioned, there were no DLTs at the *higher* doses of 160mg/m² and 200mg/m² within C3 and C4 respectively.
#AVCT
#AVCT
Some key takes from the AVA6000, ALS-6000-101 part of the presentation; presented by Dr Andrew Saunders.
1b will now be based on two different dosing levels as opposed to one, which in part explains why @Avacta have stated that they expect 1a to finish in H123.
⤵️
Context on the DLT within C2 👇🏽
‘’This was felt not to be clearly anthracycline related cardiotoxicity’’
As mentioned, there were no DLTs at the *higher* doses of 160mg/m² and 200mg/m² within C3 and C4 respectively.
#AVCT
Systemic levels of dox and plasma exposure reduced up to 90% when compared to standard dox.
Sadly, 1 patient of 19 had a DLT. This was within C2 at 120mg/m².
However, there were no DLTs at the *higher* doses of 160mg/m² and 200mg/m² within C3 and C4 respectively.
#AVCT
‘’*Huge* potential for next gen dox’’
‘’There is *considerable* scope for improvement on the profile of conventional & liposomal dox’’
‘’AVA6K can safely deliver larger doses of doxorubicin to tumour whilst sparing healthy tissues & organs’’
It’s all there, in writing.
#AVCT
3 tumour to plasma ratios greater than 100:1.
‘’These concentrations are within the therapeutic window where we might expect clinical benefit or efficacy’’
‘’Preferential concentration of dox released from AVA6K in the tumour relative to the periphery’’
#AVCT
‘’These concentrations are within the therapeutic window where we might expect clinical benefit or efficacy’’
‘’A significant concentration of dox in those tumour biopsies’’
‘’Preferential concentration of dox released from AVA6K in the tumour relative to the periphery’’
#AVCT
‘’These concentrations are within the therapeutic window where we might expect clinical benefit or efficacy’’
‘’A significant concentration of dox in those tumour biopsies’’
‘’Preferential concentration of dox released from AVA6K in the tumour relative to the periphery’’
A link to the video recording of yesterday's Therapeutics Science Day is now available on our website, along with all the presentations given. https://t.co/fuFARuon9X #AVCT
A fascinating afternoon at @avacta#AVCT’s Science Day.
Incredible presentations from globally renowned oncologists.
Decks were equally fascinating.
Standout for me:
For #AVA6000, active dox found in tumour : bloodstream… greater than 100 : 1, in multiple biopsies, IIRC.
🤯
A fascinating afternoon at @avacta#AVCT’s Science Day.
Incredible presentations from globally renowned oncologists.
Decks were equally fascinating.
Standout for me:
For #AVA6000, active dox found in tumour : bloodstream… greater than 100 : 1, in multiple biopsies, IIRC.
🤯